$393 Million is the total value of Opaleye Management Inc.'s 47 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 36.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXGN | Sell | AXOGEN INC | $47,905,000 | -33.8% | 1,300,000 | -9.7% | 12.19% | -34.9% |
| CDXS | CODEXIS INC | $30,012,000 | +19.1% | 1,750,000 | 0.0% | 7.64% | +17.1% | |
| LOXO | LOXO ONCOLOGY | $29,895,000 | -1.5% | 175,000 | 0.0% | 7.61% | -3.2% | |
| AMRN | Sell | AMARIN CORP PLCsponsored adr | $26,032,000 | +381.4% | 1,600,000 | -8.6% | 6.62% | +373.4% |
| BPMC | Sell | BLUEPRINT MEDICINES | $23,418,000 | +5.4% | 300,000 | -14.3% | 5.96% | +3.6% |
| DCPH | DECIPHERA PHARMACEUTICALS IN | $16,262,000 | -1.6% | 420,000 | 0.0% | 4.14% | -3.3% | |
| PTE | Sell | POLARITYTE INC | $14,611,000 | -22.4% | 765,000 | -4.4% | 3.72% | -23.7% |
| VKTX | Sell | VIKING THERAPEUTICS INC | $14,371,000 | +26.2% | 825,000 | -31.2% | 3.66% | +24.0% |
| FGEN | Sell | FIBROGEN INC | $12,150,000 | -46.1% | 200,000 | -44.4% | 3.09% | -47.0% |
| AGIO | AGIOS PHARMACEUTICALS | $10,025,000 | -8.4% | 130,000 | 0.0% | 2.55% | -10.0% | |
| BOLD | Buy | AUDENTES THERAPEUTICS INC | $8,907,000 | +22.7% | 225,000 | +18.4% | 2.27% | +20.6% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $8,707,000 | +17.3% | 725,000 | +31.8% | 2.22% | +15.2% |
| PTCT | PTC THERAPEUTICS INC | $8,460,000 | +39.4% | 180,000 | 0.0% | 2.15% | +37.0% | |
| AMAG | AMAG PHARMACEUTICALS INC | $8,400,000 | +2.6% | 420,000 | 0.0% | 2.14% | +0.8% | |
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $8,390,000 | -23.6% | 1,730,000 | -5.5% | 2.14% | -24.9% |
| SGMO | Sell | SANGAMO BIOSCIENCES INC | $8,305,000 | +15.8% | 490,000 | -3.0% | 2.11% | +13.8% |
| FENC | Buy | FENNEC PHARMACEUTICALS INC | $7,995,000 | -19.0% | 975,000 | +3.2% | 2.03% | -20.3% |
| MGEN | Buy | MIRAGEN THERAPEUTICS INC | $7,788,000 | +1.2% | 1,395,700 | +16.3% | 1.98% | -0.5% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $7,735,000 | -17.4% | 698,100 | +0.1% | 1.97% | -18.8% |
| XENE | New | XENON PHARMACEUTICALS INC | $7,014,000 | – | 465,200 | +100.0% | 1.78% | – |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $6,667,000 | +14.4% | 375,000 | +41.5% | 1.70% | +12.4% |
| XNCR | XENCOR INC | $6,140,000 | -7.8% | 180,000 | 0.0% | 1.56% | -9.4% | |
| RARE | ULTRAGENYX PHARMACEUTICALS INC | $6,107,000 | -0.7% | 80,000 | 0.0% | 1.55% | -2.4% | |
| XOMA | Sell | XOMA CORP DEL | $5,622,000 | -15.9% | 320,000 | -0.1% | 1.43% | -17.3% |
| OCUL | Sell | OCULAR THERAPEUTIX INC | $5,504,000 | -26.6% | 800,000 | -28.0% | 1.40% | -27.9% |
| CDTX | CIDARA THERAPEUTICS INC | $5,280,000 | -15.4% | 1,200,000 | 0.0% | 1.34% | -16.8% | |
| CORI | Sell | CORIUM INTERNATIONAL INC | $5,230,000 | -18.4% | 550,000 | -31.2% | 1.33% | -19.8% |
| CMRX | Buy | CHIMERIX INC | $4,609,000 | -15.8% | 1,185,000 | +3.0% | 1.17% | -17.2% |
| IMMY | New | IMPRIMIS PHARMACEUTICALS | $4,503,000 | – | 1,620,000 | +100.0% | 1.15% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $4,048,000 | – | 195,000 | +100.0% | 1.03% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $3,656,000 | – | 325,000 | +100.0% | 0.93% | – |
| CTIC | Buy | CTI BIOPHARMA CORP | $3,348,000 | +316.9% | 1,550,000 | +860.3% | 0.85% | +309.6% |
| CARA | New | CARA THERAPEUTICS INC | $3,113,000 | – | 130,000 | +100.0% | 0.79% | – |
| ARQL | Buy | ARQULE INC | $3,113,000 | +34.1% | 550,000 | +31.0% | 0.79% | +31.8% |
| CLLS | New | CELLECTIS SAsponsored ads | $3,104,000 | – | 110,000 | +100.0% | 0.79% | – |
| ARDX | New | ARDELYX INC | $2,827,000 | – | 650,000 | +100.0% | 0.72% | – |
| EPZM | Sell | EPIZYME INC | $2,120,000 | -43.1% | 200,000 | -27.3% | 0.54% | -44.1% |
| TGTX | Sell | TG THERAPEUTICS INC | $1,960,000 | -76.1% | 350,000 | -44.0% | 0.50% | -76.5% |
| PLX | Sell | PROTALIX BIOTHERAPEUTICS INC | $1,817,000 | +36.3% | 2,500,000 | -19.4% | 0.46% | +33.9% |
| CMTA | New | CLEMENTIA PHARMACEUTICAL INC | $1,660,000 | – | 148,832 | +100.0% | 0.42% | – |
| TCDA | New | TRICIDA INC | $1,558,000 | – | 51,000 | +100.0% | 0.40% | – |
| BFRA | Sell | BIOFRONTERA AGsponsored adr | $1,073,000 | -77.4% | 79,007 | -79.8% | 0.27% | -77.8% |
| DERM | New | DERMIRA INC | $1,061,000 | – | 97,400 | +100.0% | 0.27% | – |
| ACHN | New | ACHILLION PHARMACEUTICALS INC | $1,012,000 | – | 275,000 | +100.0% | 0.26% | – |
| INFI | New | INFINITY PHARMACEUTICALS INC | $745,000 | – | 275,000 | +100.0% | 0.19% | – |
| FOMX | Sell | FOAMIX LTD | $521,000 | -86.4% | 91,000 | -63.6% | 0.13% | -86.6% |
| BLRX | BIOLINERX LTDsponsored adr | $267,000 | +20.3% | 250,000 | 0.0% | 0.07% | +19.3% | |
| AZRX | Exit | AZURRX BIOPHARMA INC | $0 | – | -130,000 | -100.0% | -0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.